Study on Personalized Chemotherapy for Pancreatic Cancer Using RNA Profiling

Sponsor: Medical College of Wisconsin

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04683315

Provider View

This clinical trial is exploring a personalized approach to chemotherapy for patients with pancreatic cancer that can be surgically removed or is borderline removable. The study uses RNA profiling to determine the best chemotherapy treatment based on the cancer's subtype.

Patient Parameters

Program Overview

This study is testing a new way to personalize chemotherapy for patients with pancreatic cancer that can be surgically removed or is borderline removable. By analyzing RNA from a sample taken during an endoscopic ultrasound, doctors can identify the cancer's subtype. Based on this information, patients will receive one of two standard chemotherapy treatments: mFOLFIRINOX for the classical subtype or gemcitabine/nab-paclitaxel for the basal subtype.

Description

In this study, researchers are using a technique called PurIST to analyze RNA from pancreatic cancer samples taken during an endoscopic ultrasound. This analysis helps determine the cancer's subtype, which guides the choice of chemotherapy. Patients with the classical subtype will receive a chemotherapy regimen called mFOLFIRINOX, while those with the basal subtype will receive a different regimen, gemcitabine/nab-paclitaxel. The goal is to tailor treatment to the specific characteristics of each patient's cancer, potentially improving outcomes.

Eligibility Criteria

Exclusion Criteria

  • Have received chemotherapy or radiation within the last three years.
  • Have had another type of cancer (except for certain skin cancers or localized prostate cancer) within the last three years.
  • Have uncontrolled health conditions, such as serious infections, heart failure, unstable heart conditions, psychiatric issues, or extreme obesity (BMI over 55).
  • Have known infections like HIV, hepatitis B, or hepatitis C.
  • Are pregnant or breastfeeding, or are of childbearing potential and not using contraception for four weeks before treatment.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.